in Newswire September 17, 2019

Sanofi, Boehringer Ingelheim Hit with Class Action Over Allegedly Unsafe Levels of Probable Carcinogen NDMA in Zantac

Garza et al. v. Sanofi-Aventis U.S. LLC et al.

Filed: September 13, 2019 § 5:19-cv-05772

Zantac makers Sanofi-Aventis U.S. and Boehringer Ingelheim face a class action over the allegedly high NDMA content in the over-the-counter heartburn and indigestion drug.

Last Updated on September 17, 2019 — 11:09 AM

Corrado Rizzi

corrado@classaction.org

Corrado Rizzi is the Managing Editor and a writer for ClassAction.org.

About ClassAction.org

ClassAction.org is a group of online professionals (designers, developers and writers) with years of experience in the legal industry.

Learn More

Before commenting, please review our comment policy.